This study is designed to assess the safety, tolerability and efficacy of TOP1630 ophthalmic solution in subjects with Dry Eye Syndrome.~Eligible subjects will be randomized double masked to either TOP1630 or placebo.~Part 1 (time frame 12 days) comprises assessment of safety, tolerability and ocular comfort.~Part 2 (time frame 35 days) comprises assessment of safety, tolerability and efficacy
In subjects with Dry Eye Syndrome:~The primary objective of this study is to compare the safety and tolerability of TOP1630 Ophthalmic Solution to placebo.~The secondary objectives are to compare the efficacy of TOP1630 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye syndrome.